Pharmafile Logo

Astellas Pharma Inc

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Astellas Pharma Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Astellas Pharma Inc.

Recent articles on PMLiVE featuring Astellas Pharma Inc

- PMLiVE
ESMO 2025 – ensuring innovation isn’t lost in translation

This year marks the congress’s 50th anniversary, with the theme: Many journeys. One global community

- PMLiVE
Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE
Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

Approximately 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE
Bridging gaps and breaking barriers in pharma alliances

The future of healthcare will be forged on collaboration

- PMLiVE
Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

- PMLiVE
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

About 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE
Astellas’ Vyloy combination approved by EC as first-line gastric cancer treatment

Approximately 136,000 cases of the disease are diagnosed in Europe every year

- PMLiVE
Astellas’ Vyloy combination approved by MHRA as first-line gastric cancer treatment

Approximately 6,600 new cases of the disease are diagnosed in the UK every year

- PMLiVE
Astellas’ zolbetuximab combination receives positive CHMP opinion for advanced gastric cancer

Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe

- PMLiVE
Women’s health – managing the menopause

PME spoke to Marci English, Vice President and Head of BioPharma Development, Astellas, about the importance of new treatments for menopause symptoms, the unmet need and the company’s commitment to midlife women’s health

- PMLiVE
2024 PM Society Awards – winners announced

Havas Lynx takes three Golds and AstraZeneca tops the client leaderboard for the second year

- PMLiVE
Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m

As part of the deal, Xyphos will combine its iGPS system with Kelonia’s ACCEL technology

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links